KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.